Redefining the Frontline, Reframing the Second Line, and Recalibrating Risk-Benefit Assessments in EGFR-Mutant NSCLC

Osimertinib (Tagrisso) became the default first-line standard of care for patients with EGFR-mutant advanced non–small cell lung cancer (NSCLC) after results from the phase 3 FLAURA trial (NCT02296125) showed durable disease control, central nervous system (CNS) activity, and a manageable safety profile with the third-generation EGFR TKI. However, as data continue to mature, the field is entering a new era, one where the central question is no longer whether osimertinib works, but whether osimertinib monotherapy is appropriate for every patient.

In an OncLive® Scientific Interchange and Workshop, moderator Narjust Florez, MD, FASCO, and faculty discussed how the treatment paradigm is increasingly splitting into 2 strategic directions: a combination-based approach designed to maximize early disease control, and a more individualized model that reserves intensification for patients at highest risk of early progression.¹

Florez is the associate director of the Cancer Care Equity Program, codirector of the Young Lung Cancer Program, assistant professor of medicine at Harvard Medical School, and thoracic medical oncologist at Dana-Farber Cancer Institute, in Boston, Massachusetts.

Faculty included:

• Jessica Lin, MD, medical oncologist and associate professor of medicine at Harvard Medical School, and attending physician at the Center for Thoracic Cancers and the Henri and Belinda Termeer Center for Targeted Therapies at Massachusetts General Hospital in Boston;
• Edgardo S. Santos, MD, FACP, FASCO, medical director for Broward County at the Oncology Institute of Hope and Innovation, clinical associate professor of medical and thoracic oncology at the Charles E. Schmidt College of Medicine at Florida Atlantic University, vice president of the Florida Society of Clinical Oncology (FLASCO), and president of the FLASCO Foundation;
• Julia Rotow, MD, assistant professor at Harvard Medical School, and clinical director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute in Boston, Massachusetts;
• Christine M. Lovly, MD, PhD, associate professor of medicine in hematology/oncology and the Ingram-Associate Professor of Cancer Research at Vanderbilt-Ingram Cancer Center in Nashville, Tennessee; and
• Jonathan W. Lee, MD, MSc, chief hematology/oncology fellow in the Division of Hematology and Medical Oncology at Weill Cornell Medicine in New York, New York.

How has decision-making for frontline EGFR-mutant NSCLC changed?

In 2026, EGFR-mutant advanced NSCLC is no longer a disease with 1 frontline regimen. In the first-line setting, options include osimertinib monotherapy, osimertinib in combination with pemetrexed and platinum-based chemotherapy, and amivantamab-vmjw (Rybrevant) plus lazertinib (Lazcluze).^2,3

With multiple options, frontline therapy is increasingly shaped by updated efficacy and safety data from pivotal phase 3 trials, including FLAURA2 (NCT04035486) and MARIPOSA (NCT04487080), which introduced osimertinib plus chemotherapy and amivantamab and lazertinib into the first-line setting, respectively.

Since both approvals, a question that has been introduced is whether combination therapy should be the new standard, or whether it should be reserved for select patients with high-risk clinical features?

“All my patients are on combination therapy. Combination therapy is the way to go. You cannot compete against the overall survival [OS] unless the patient tells you something different or the patient has some other issues,” Santos said.

What are the advantages of the FLAURA2 regimen?

FLAURA2 represents one of the clearest examples of first-line intensification in EGFR-mutant advanced NSCLC. The phase 3 trial evaluated osimertinib plus platinum and pemetrexed chemotherapy vs osimertinib monotherapy, demonstrating improved progression-free survival (PFS) with the combination regimen vs osimertinib alone by blinded independent central review (HR, 0.62; 95% CI, 0.48-0.80).⁴

“It’s an advantage of FLAURA2 that you can say, we’ll just start [with the] TKI and talk again in 7 to 10 days when you’re probably going to be feeling better and then we’ll talk about chemotherapy,” Rotow said.

Although PFS remains a central efficacy end point, the discussion around FLAURA2 has broadened with the availability of updated analyses looking at outcomes in patients with baseline CNS metastases, according to pemetrexed exposure, and updated overall survival (OS) analyses. In findings presented at the 2024 IASLC World Conference on Lung Cancer (WCLC), 2025 European Lung Cancer Conference, and 2025 IASLC WCLC, data showed that the combination improved PFS in patients with baseline CNS metastases (HR, 0.47; 95% CI, 0.33-0.66), those with longer exposure to pemetrexed (≥18 months, median PFS: 30.6 months; 95% CI, 27.4-not calculable), and OS in all-comers (HR, 0.77; 95% CI, 0.61-0.96; P = .02).^4,5,6

“I let the kidneys be my guide to try to get as much pemetrexed,” Lovly said. “I would be cautious about using these data to conclude however, that longer treatment duration with pemetrexed is associated with significantly increased PFS beyond the 3-month cutoff,” Lin added.

The emergence of post-progression end points such as time to first subsequent treatment (TFST; HR, 0.73; 95% CI, 0.56-0.94) and time to second subsequent treatment (TSST; HR, 0.69; 95% CI, 0.51-0.93), both of which favored the combination in FLAURA2, is also relevant to decisions in the real-world setting.⁴ These measures help clarify whether intensification meaningfully delays the need for later-line therapy and potentially alters the downstream treatment sequence.

The exploratory OS analysis presented at the 2025 ESMO Congress focusing on patients with poorer prognostic factors also reinforced that the combination provided a consistent survival benefit regardless of baseline prognostic factors.⁷

Taken collectively, the consensus was that the FLAURA2 regimen is strongest in patients with aggressive disease biology, high tumor burden, or baseline CNS involvement, scenarios where maximizing early systemic and intracranial disease control is a priority.

However, the faculty also recognized the cost of intensification, measured by increased toxicity, increased monitoring requirements, and increased treatment burden for patients.

How has the MARIPOSA trial redefined first-line EGFR treatment strategies?

The MARIPOSA trial has gained attention not only because of its efficacy results, but because it offers the possibility of enhanced disease control through dual pathway targeting without traditional cytotoxic chemotherapy. Key findings from the trial illustrated that the combination led to improved OS (HR, 0.75; 95% CI, 0.61-0.92; P = .005), intracranial PFS (HR, 0.79; 95% CI, 0.61-1.02), and time to symptomatic progression (HR, 0.69; 95% CI, 0.57-0.83; P < .001) vs osimertinib monotherapy.^8,9 Moreover, the median duration of response was improved with the combination, at 35.7 months (95% CI, 25.8-not evaluable) vs 29.6 months (95% CI, 23.9-34.1) with osimertinib alone.⁸ 

Findings presented at the 2025 European Lung Cancer Conference also suggested that dose interruptions did not affect the efficacy of the regimen, with a median PFS of 23.9 months (95% CI, 18.5-not evaluable [NE]) and 23.7 months (95% CI, 18.4-NE) in patients with (n = 206) and without (n = 215) dose interruptions in the first 4 months of therapy. Moreover, the 2-year PFS rate was 52% in both arms.⁹

The faculty underscored the final OS results, explaining that the OS maturity of MARIPOSA positions the regimen to play a larger role in frontline decision-making discussions.

Although the trial reinforces the shift away from the long-standing assumption that the best first-line EGFR strategy is a single-agent TKI, it also showcases the operational demands that are required for administration, including infusion-based therapy and adverse effects (AEs) that can require proactive patient education and supportive management.

“What worries me [are] the AEs that have forced me to hold amivantamab significantly [such as] low albumin,” Florez said.

What is the best way to define risk-benefit in 2026?

As frontline EGFR-directed therapy continues to expand, the concept of risk-benefit must evolve beyond traditional efficacy end points toward three practical considerations: who is the patient, how aggressive is their disease, and what toxicity profile is most manageable over time?

Age, comorbidities, functional status, baseline frailty, and social support can all influence whether a patient can realistically tolerate combination therapy. The faculty noted that a regimen that is highly effective on paper may not be appropriate for a patient with limited ability to attend frequent infusion visits or manage high-intensity supportive care needs.

With respect to disease biology, baseline CNS metastases, high-volume systemic disease, symptomatic tumor burden, and visceral involvement often push oncologists toward intensification. The faculty explained that the most compelling rationale for combination therapy is not simply extending PFS but improving CNS disease control and delaying neurologic progression which can irreversibly compromise quality of life (QOL).

When it comes to toxicity, the faculty noted that osimertinib plus chemotherapy introduces predictable hematologic and chemotherapy-associated toxicities, whereas MARIPOSA introduces a different toxicity burden that may emerge early and persist over time. But they all agreed that toxicity risk-benefit is not defined solely by the rate of grade 3 or greater AEs. It is defined by what leads to dose interruptions, discontinuation, treatment delays, and long-term compromise in QOL.

How is the evolving frontline setting reshaping the second line?

Perhaps the most practice-changing consequence of frontline intensification is its downstream effect on second-line therapy.

As more patients receive combination regimens earlier, the second-line setting becomes more complex. The traditional approach of osimertinib followed by platinum and pemetrexed chemotherapy may no longer represent the most common pathway, particularly if patients receive chemotherapy or amivantamab-based therapy upfront.

Second-line options now under consideration with these additions in the first line include amivantamab plus chemotherapy, osimertinib plus chemotherapy, antibody-drug conjugates (ADCs) such as datopotamab deruxtecan-dlnk (Dato-DXd; Datroway), ivonescimab, and MET-directed combination strategies.

The decision is increasingly influenced by what is used in the first line, with amivantamab plus chemotherapy and osimertinib plus chemotherapy representing key considerations in patients with disease progression after osimertinib. However, the faculty also noted that ADCs and biomarker-agnostic therapies may become more prominent, especially when resistance patterns are unclear or tissue access is limited.

Ultimately, the available data reinforce that the frontline setting is becoming less about selecting a single best regimen and deciding whether the goal is maximizing early disease control through intensification or maintaining a more tolerable regimen while preserving downstream options. The faculty agreed osimertinib monotherapy remains an appropriate option for patients with lower-risk disease or those prioritizing tolerability, whereas the addition of chemotherapy may be most relevant for patients with aggressive disease biology, high-volume disease, or higher-risk clinical features.

Amivantamab plus lazertinib can be introduced if a non-chemotherapy combination approach is preferred but requires careful toxicity management and operational planning.

“I believe FLAURA2 has the edge, but I do think [subcutaneous administration] in the real world is going to draw some patients [to amivantamab and lazertinib]. In the second-line setting, we talked about it becoming more complex, but we’re using Dato-DXd now. I think it fills an important gap, but I think there could be a lot of evolution in second and third lines of therapy in the coming years,” Rotow said.

As efficacy signals mature across frontline trials, the risk-benefit discussion is becoming increasingly patient-specific, and the most effective EGFR strategy is not simply the regimen with the best curve, it’s the regimen that fits the patient’s clinical risk profile, aligns with their goals, and preserves a coherent sequencing plan when progression eventually occurs.

References

1. Addressing key treatment questions in EGFR-mutant advanced NSCLC. An OncLive Scientific Interchange and Workshop. OncLive. October 17, 2025. Accessed February 13, 2026.
2. Tagrisso. Prescribing information. AstraZeneca; 2024. Accessed February 13, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf
3. FDA approves lazertinib with amivantamab-vmjw for non-small lung cancer. FDA. Updated August 20, 2024. Accessed February 13, 2026. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lazertinib-amivantamab-vmjw-non-small-lung-cancer
4. Valdiviezo N, Gray JE, Jänne PA, et al. FLAURA2: impact of tumor burden on outcomes of first-line osimertinib ± chemotherapy in patients with EGFR-mutated advanced NSCLC. J Thorac Oncol. 2024;19(10):S102. doi:10.1016/j.jtho.2024.09.185
5. Planchard D, Cheng Y, Kobayashi K, et al. Characterisation of benefit-risk by pemetrexed (pem) exposure in patients (pts) with EGFRm aNSCLC treated with 1L osimertinib (osi) + platinum-pem in FLAURA2. J Thorac Oncol. 2025;20(3):S43-S44. doi:10.1016/S1556-0864(25)00248-5
6. Planchard D, Jänne PA, Kobayashi K, et al. First-line osimertinib + chemotherapy versus osimertinib monotherapy in EGFRm advanced NSCLC: FLAURA2 final overall survival. Presented at: International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer; September 6-9, 2025; Barcelona, Spain. Abstract PL02.06.
7. Jänne PA, Planchard D, Kobayashi K, et al. FLAURA2: exploratory overall survival analyses in patients with poorer prognostic factors treated with osimertinib ± platinum-pemetrexed as first-line treatment for EGFR-mutated advanced NSCLC. Presented at: 2025 ESMO Congress; October 17-21, 2025; Berlin, Germany. Abstract LBA77.
8. Yang JCH, Lu S, Hayashi H, et al. Overall survival with amivantamab-lazertinib in EGFR-mutated advanced NSCLC. N Engl J Med. 2025;393(17):1681-1693. doi:10.1056/NEJMoa2503001
9. Yang JCH, Kim YJ, Lee SH, et al. Amivantamab plus lazertinib vs osimertinib in first-line (1L) EGFR-mutant (EGFRm) advanced NSCLC: final overall survival (OS) from the phase III MARIPOSA study. J Thorac Oncol. 2025;20(3):S6-S8. oi:10.1016/S1556-0864(25)00199-6